Virus weaponized to fight rectal cancer in new trial
Disease control
Recruiting now
This early-stage trial is testing whether adding a new experimental therapy called NG-350A to standard chemoradiation is safe and effective for people with locally advanced rectal cancer. NG-350A is a specially engineered virus designed to target the tumor and activate the immune…
Phase: PHASE1 • Sponsor: Akamis Bio • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC